Teva pharmaceutical Industries Ltd. Announces September Conference Call to Detail Promising Phase 3 Olanzapine LAI Trial Results
Teva Pharmaceutical Industries Ltd. will host a conference call on September 22, 2025, to discuss data from the completed Phase 3 SOLARIS trial evaluating TEV-‘749, a long-acting injectable (LAI) formulation of olanzapine. The announcement follows presentations of the trial findings at the Psych Congress Annual Meeting.
The SOLARIS trial data represents a possibly notable advancement in the treatment of schizophrenia and bipolar I disorder.Olanzapine LAI offers a sustained-release formulation designed to improve medication adherence, a critical challenge in managing these chronic mental health conditions. Accomplished results could provide a new, more effective treatment option for patients and address a ample unmet medical need. Teva’s commitment to expanding its innovative medicines pipeline, including biosimilars, is central to its “Pivot to Growth” strategy. Investors and healthcare professionals will be keenly focused on the detailed data presented during the call, as it will inform assessments of the drug’s potential market impact and Teva’s overall financial outlook.
The conference call will provide a comprehensive review of the Phase 3 trial results, including efficacy and safety data. Details regarding access to the call will be forthcoming.
Media Inquiries:
TevaCommunicationsNorthAmerica@tevapharm.com
investor Relations Inquiries:
TevaIR@Tevapharm.com
